TPA, TATI, CEA, AFP, β-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 3, 1996, Pages 271-277

  Pectasides, D ^a   Bafaloucos, D ^a   Antoniou, F ^a   Gogou, L ^a   Economides, N ^a   Varthalitis, J ^a   Dimitriades, M ^a   Kosmidis, P ^a   Athanassiou, A ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Bladder carcinoma; Tumor associated antigens

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; APROTININ; CA 19-9 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR ANTIGEN; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; CYSTECTOMY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MONITORING; RADIOIMMUNOASSAY; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, TRANSITIONAL CELL; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; SERPINS; TISSUE POLYPEPTIDE ANTIGEN; TRYPSIN INHIBITOR, KAZAL PANCREATIC; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0029954644     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199606000-00013     Document Type: Article

References (27)

1. Adolphs HD, Oehr P. Significance of urine and serum TPA determination for the diagnosis of urinary bladder cancer. Tumor Diagnostic 1982;2:34-9.
2. Adolphs HD, Oehr P. Significance of plasma tissue polypeptide antigen determination for diagnosis and follow-up of urothelial bladder cancer. Urol Res 1984;12:125-8.
3. Costello CB, Kumar S. Prognostic value of tissue polypeptide antigen in urological neoplasia. J Roy Soc Med 1985;78:207-10.
4. Oehr P, Adolphs HD. Urogenital cancer. In: Lüthgens M, Schlegel G, eds. Clinical use of the tumor marker system CEA-TPA. Tumor Diagnostic. Germany: H.D. Adolphs-Leonberg, Verlag, 1989: 99-119.
5. Vogel J, Oehr P, Maisey R, Adolphs HD. Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinoma and in tumor free urothelium of the urinary bladder. Cancer Detect Prev 1988;11:389-96.
6. Dexeus F, Logothetis C, Hossan E, Samuels ML. Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. J Urol 1986;136:403-7.
7. Tailly G, Cornelissen M, Vereecken RL, Verduyn H, Devos P, De Roo M. Urinary carcinoembryonic antigen (CEA) in the diagnosis and follow-up of bladder carcinoma. Br J Urol 1983;55: 501-7.
8. Halila H, Lehtovirta P, Stenman UH. Tumour associated trypsin inhibitor in ovarian cancer. Br J Cancer 1988;57:304-7.
9. Arapantoni-Dadioti P. Prostatic specific antigen as a reliable marker. Lecture at the OECI (Organisation of European Cancer Institutes) Meeting of Pathology Group (Brussels), May 1989 (unpublished).
10. Kato H, Torigoe T. Radioimmunoassay for tumour antigen of human cervical squamous cell carcinoma. Cancer 1977;41: 1621-8.
11. Ikemoto S, Iimori H, Nishimoto K, Hayahara N, Okamoto S. Two cases of urothelial tumour with high serum level of carcinoembryonic antigen and TA-4. Urologia Intern 1993;51: 105-7.
12. Del Villano B, Brenna S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody denned tumor marker CA 19-9. Clin Chem 1983;29:549-52.
13. Cooper EH, Knowles JC, Parker D, Taylor M. An evaluation of CA 50 levels in cancer using a time-resolved fluoroimmunoassay. Biomed Pharmacother 1988;42:189-93.
14. Lipponen PK, Eskelinen MJ. Expression of CA-50 antigen as a prognostic variable in transitional cell bladder cancer. Br J Urol 1993;71:192-8.
15. Lipponen PK, Eskelinen MJ, Collan Y. Immunohistochemical staining of CA-50 antigen in human bladder cancer. Relation to histologic grade, clinical stage, and prognosis. Urology 1991;38: 163-9.
16. Sakai H, Toyofuku K, Vogi Y, Minami Y, Kanetake H, Saito Y. Carbohydrate antigen 19-9 and carcinoembryonic antigen-producing transitional cell carcinoma of the ureter and bladder: a case report. J Urol 1993;150:182-4.
17. Ozkardes H, Ergen A, Ozen HA, Ayhan A, Remzi D. Immunohistochemical detection of beta-human chorionic gonadotropin in urothelial carcinoma. Int Urol Nephrol 1991;23:5-11.
18. Norusis M/SPSS for Win. Base system user's guide, Release 6.0 (1993). Contractor/manufacturer: SPSS Inc., 444 N. Michigan Ave., Chicago, IL 60611.
19. Norusis M/SPSS for Win. Advanced statistics, Release 6.0 (1993). Contractor/manufacturer: SPSS Inc., 444 N. Michigan Ave., Chicago, IL 60611.
20. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
21. Pectasides D, Economides N, Bourazanis J, et al. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor and carcinoembryonic antigen for monitoring cervical cancer. Am J Clin Oncol 1994;17:307-12.
22. Pectasides D, Bourazanis J, Economides N, Pozadzidou L, Koutsiouba P, Athanassiou A. Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA) and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer. Int J Biol Markers 1993;8:81-7.
23. Golz R, Schubert GE. Prostatic specific antigen. Immunoreactivity in urachal remnants. J Urol 1989;141:1480-2.
24. Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordonez NG. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67:2165-72.
25. Iles RK, Chard T. Human chorionic gonadotropin expression by bladder cancers: biology and clinical potential. J Urol 1991;145:453-8.
26. Colleen S, Ek A, Gullberg B, Johansson BG, Lindberg LG, Olsson AM. CEA in urine in patients with urothelial carcinoma. Scand J Urol Nephrol 1979;13:149-53.
27. Pohl AL, Schweiger CHR, Maenner G, et al. Selection of tumor markers by multivariate analysis for diagnosis of urinary bladder cancer [Abstract 34]. In: Proceedings of the 10th IATMO (International Assn. of Tumor Markers in Oncology) International Conference on human tumour markers, Bonn, Germany, September 1993.